Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.
about
MR spectroscopy indicates diffuse multiple sclerosis activity during remissionHuman herpesvirus 6 infection as a trigger of multiple sclerosisWhite matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosisVirus-mediated autoimmunity in Multiple Sclerosis.The Possible Future Roles for iPSC-Derived Therapy for Autoimmune DiseasesAt the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities onlyThe retrovirus/superantigen hypothesis of multiple sclerosis.New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis.Functional magnetic resonance imaging.The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.Autologous hemopoietic stem cell transplantation for multiple sclerosis: is it worthwile?Proton magnetic resonance spectroscopy in multiple sclerosis.Global N-acetylaspartate declines even in benign multiple sclerosisLongitudinal MR spectroscopy of neurodegeneration in multiple sclerosis with diffusion of the intra-axonal constituent N-acetylaspartate.Temporal pattern of plasma membrane calcium ATPase 2 expression in the spinal cord correlates with the course of clinical symptoms in two rodent models of autoimmune encephalomyelitis.Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy.A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.Sex differences in autoimmune diseases.Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE.Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?Estrogen and testosterone therapies in multiple sclerosis.Using diffusion tensor imaging and immunofluorescent assay to evaluate the pathology of multiple sclerosis.Longitudinal whole-brain N-acetylaspartate concentration in healthy adults.Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosisMultiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.Reduced expression of plasma membrane calcium ATPase 2 and collapsin response mediator protein 1 promotes death of spinal cord neuronsSub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetateClinically isolated syndromes suggestive of multiple sclerosis: an optical coherence tomography study.Application of laser radiation and magnetostimulation in therapy of patients with multiple sclerosis.Mitoxantrone (Novantrone) in multiple sclerosis: new insights.Glatiramer acetate in multiple sclerosis.The basis for treatment in multiple sclerosis.Evaluation of corticospinal axon loss by fluorescent dye tracing in mice with experimental autoimmune encephalomyelitisCerebrospinal fluid lactate is associated with multiple sclerosis disease progression.Brain atrophy in multiple sclerosis: what we know and would like to know.
P2860
Q24615946-E453ACD0-8CF8-4764-9DC0-C72B712AF701Q24620734-253FB242-0EB0-4F75-99DD-CA29D8898A27Q24642079-9D474DE4-E785-42BF-B970-68BBF39985A5Q25256901-370E39AA-C05E-4188-80E9-ADDD23A3A487Q26799472-E217F7A7-397B-4B00-9458-C1CB0720954CQ28265516-8A066E79-C278-461C-8F75-404673546A56Q30317136-A42A4A05-FE8F-4BF0-B44C-9B12A37DD745Q30597559-BAC4CD1A-D3CD-4A82-A280-6039BE634CE4Q30887079-CC27E244-4BBC-457A-A4EE-3650FDA7E548Q30953733-C037A0D1-177D-4B09-9351-908A2FA8D849Q30983016-15C09BE8-1335-41E5-B8E0-674DF7AA8A2BQ31132463-CCAB4711-8D22-47BD-ADD7-51D1FE3F7FC2Q33380269-7D7AAD43-84B0-47E2-998E-077826BCB3EFQ33390863-A6A05EC7-4C43-4BB1-9C04-7DB0ED5E5B5AQ33725131-F42159BC-DE9B-4FEA-BE9C-B54C7E011F67Q33869743-3C5F989B-11FC-4B8D-B286-453C11B1165CQ33958566-4D88CB76-15CD-4F1C-905A-747C4B08306FQ34264279-7498A5EE-26B9-4DBE-B0EF-1B62970E4CAAQ34409308-95EEF602-9C4B-4EBF-B2BF-180942A8E56CQ34459729-E0B1307D-24DA-4AD8-A7FA-3EC2E8794B27Q34483022-DEC5F352-D02B-4BCF-8961-B073E211714EQ34498866-4778FE78-2784-4F9D-B058-79E075A8D7BDQ34552395-86704CEF-2372-488E-B74E-23EACAD21116Q34570124-90E7D501-5FE0-4AD7-BB1D-ABD459B7E0C9Q34610594-AE12AB11-BD75-40C2-9E10-1A12A339ACDCQ34823496-90E94CE7-08FE-4368-A74A-11DBA5CA559DQ35086279-A49B3876-A252-4C87-8D1D-92E187F75DB6Q35212994-E46DA6B6-5486-4BB4-BDCC-44CF41EAF8EFQ35330799-CAD35F65-D0D1-4EC7-B121-F7D24548581BQ35629319-3429E093-AD0F-433F-AB81-75FD3DA0DE56Q35698250-482759B4-B8CE-4138-97DC-1EFB21001D0CQ35801041-AFD9E7A7-314E-49C7-8876-BA97CC388C29Q35842564-A740F41D-5E31-45E1-8A79-1C0F039C0F7AQ35938677-B0A7413F-3871-42ED-B97C-6399DF76DCD4Q36107235-90AE64DC-CC99-427F-97A4-0EDFF1589306Q36198583-10CDB0F7-785C-43BE-BEBA-337BD19DD34FQ36459498-E18FD6FB-047A-40AD-96A0-9B3D0ADA95F6Q36492135-69CF6A45-56FE-43EF-93A8-EAAF713082B5Q36570149-857D0E35-EB2E-4DF0-A44B-D37A99A33931Q36722172-9F2722EA-B795-4F75-B73D-A755ED1AB9E2
P2860
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@ast
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@en
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@nl
type
label
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@ast
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@en
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@nl
prefLabel
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@ast
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@en
Evidence for widespread axonal ...... l stage of multiple sclerosis.
@nl
P2093
P50
P356
P1433
P1476
Evidence for widespread axonal ...... al stage of multiple sclerosis
@en
P2093
P304
P356
10.1093/BRAIN/AWG038
P407
P577
2003-02-01T00:00:00Z